Astellas starts a second pivotal degrader trial
The latest study will test setidegrasib versus docetaxel in second-line lung cancer.
Verastem keeps investors waiting in KRAS
The company now needs to carry out separate phase 2s of its G12D inhibitor VS-7375.
Toxicity doesn't stop Incyte
The company has started a pivotal trial of its KRAS G12D inhibitor in pancreatic cancer.
Arvinas seeks to outdo Astellas
Early data are coming with the KRAS G12D degrader ARV-806.
Astellas makes its KRAS degrader choice
The company discontinues one of its two KRAS G12D degraders.
Revolution shows its selective hand
The company will start three phase 3 trials of its G12D project this year.
ASCO-GI – Astellas focuses on a degrader-chemo combo
A pivotal trial will test the KRAS G12D degrader setidegrasib plus chemo in first-line PDAC.
